ISS pans Elan plans; Elan secures Royalty ban
This article was originally published in Scrip
Elan has obtained injunctions in the US and Ireland against hostile bidder Royalty Pharma, blocking it from consummating its tender offer or sending its proxy statement to Elan shareholders. The Irish firm's complaint is that Royalty has failed to disclose information, such as the identity of its investors and details of what Royalty plans to do with Elan should it acquire a majority, which is required under Irish and US law.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.